Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

[Efficacy of tianmaixiaoke tablets in the treatment of newly diagnosed type 2 diabetes mellitus in China].

Shao C, Lü XF, Xiao XH, Xu ZR, Yang ZJ, Wang P, Liu XL, Yang WY.

Zhonghua Yi Xue Za Zhi. 2012 Jun 12;92(22):1522-6. Chinese.

PMID:
22944053
2.

Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes.

Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, Feng J.

Diabetes. 1997 Nov;46(11):1786-91.

PMID:
9356027
3.

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 May;14(5):409-18. doi: 10.1111/j.1463-1326.2011.01530.x. Epub 2011 Dec 22.

PMID:
22059736
4.

Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.

Lim S, An JH, Shin H, Khang AR, Lee Y, Ahn HY, Yoon JW, Kang SM, Choi SH, Cho YM, Park KS, Jang HC.

Clin Endocrinol (Oxf). 2012 Aug;77(2):215-23. doi: 10.1111/j.1365-2265.2011.04240.x.

PMID:
21955147
5.

[Efficacy and safety of extended-release metformin in treatment of type 2 diabetes mellitus].

Zhang JP, Yang WY, Hong TP, Yang JK, Xiao WH, Gao HW, Yang Y.

Zhonghua Yi Xue Za Zhi. 2007 May 15;87(18):1238-40. Chinese.

PMID:
17686255
6.

Effect of chromium-enriched yeast on fasting plasma glucose, glycated haemoglobin and serum lipid levels in patients with type 2 diabetes mellitus treated with insulin.

Racek J, Sindberg CD, Moesgaard S, Mainz J, Fabry J, Müller L, Rácová K.

Biol Trace Elem Res. 2013 Oct;155(1):1-4. doi: 10.1007/s12011-013-9758-9. Epub 2013 Aug 7.

PMID:
23921483
7.

Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.

Aso Y, Ozeki N, Terasawa T, Naruse R, Hara K, Suetsugu M, Takebayashi K, Shibazaki M, Haruki K, Morita K, Inukai T.

Transl Res. 2012 Jan;159(1):25-31. doi: 10.1016/j.trsl.2011.09.005. Epub 2011 Oct 17.

PMID:
22153807
8.

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.

Metabolism. 2010 Jun;59(6):887-95. doi: 10.1016/j.metabol.2009.10.007. Epub 2009 Dec 16.

PMID:
20015525
9.

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.

Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 Aug;14(8):745-52. doi: 10.1111/j.1463-1326.2012.01594.x. Epub 2012 Apr 17.

PMID:
22405352
12.

Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes.

Öz Ö, Kıyıcı S, Ersoy C, Cander S, Yorulmaz H, Gül CB, Ünal OK, Sarandol E, Kırhan E, Sığırlı D, Ertürk E, Tuncel E, Imamoğlu S.

Diabetes Res Clin Pract. 2011 Nov;94(2):212-6. doi: 10.1016/j.diabres.2011.07.031. Epub 2011 Aug 19.

PMID:
21855160
14.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group..

Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26.

PMID:
17593236
15.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
16.

The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.

Yang W, Guan Y, Shentu Y, Li Z, Johnson-Levonas AO, Engel SS, Kaufman KD, Goldstein BJ, Alba M.

J Diabetes. 2012 Sep;4(3):227-37. doi: 10.1111/j.1753-0407.2012.00213.x.

PMID:
22672586
17.

Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent.

Lirussi F, Beccarello A, Zanette G, De Monte A, Donadon V, Velussi M, Crepaldi G.

Diabetes Nutr Metab. 2002 Aug;15(4):222-31.

PMID:
12416659
19.

Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes.

Albarracin CA, Fuqua BC, Evans JL, Goldfine ID.

Diabetes Metab Res Rev. 2008 Jan-Feb;24(1):41-51.

PMID:
17506119
20.

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

Olansky L, Reasner C, Seck TL, Williams-Herman DE, Chen M, Terranella L, Mehta A, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2011 Sep;13(9):841-9. doi: 10.1111/j.1463-1326.2011.01416.x.

PMID:
21535346

Supplemental Content

Support Center